Tesamorelin

Overview

Tesamorelin is an FDA-approved synthetic analog of GHRH used to reduce excess abdominal fat in HIV-associated lipodystrophy. It is the only GHRH analog with current FDA approval and is increasingly used off-label in anti-aging and metabolic health contexts.

Mechanism of Action

Tesamorelin binds to GHRH receptors on the anterior pituitary, stimulating the synthesis and release of endogenous growth hormone. The trans-3-hexenoic acid modification enhances stability and receptor binding affinity compared to native GHRH.

Research Summary

FDA-approved in 2010 for HIV-associated lipodystrophy based on Phase 3 trials demonstrating a 15% reduction in visceral adipose tissue. Studies also show improvements in trunk fat, lipid profiles, and IGF-1 levels. Cognitive benefits have been observed in APOE4-positive patients at risk for Alzheimer's disease.

Dosing Information

Reported Side Effects

• Injection site reactions (redness, swelling, pain)
• Joint pain or stiffness
• Peripheral edema
• Paresthesia (tingling or numbness)
• Elevated IGF-1 levels

Research References

• Tesamorelin for the treatment of HIV-associated lipodystrophy (2010)
• Effects of tesamorelin on body composition and metabolic parameters in HIV-infected patients (2014)
• Growth hormone-releasing hormone treatment for cognition in adults at risk for Alzheimer's disease (2012)